The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

Phase I

9899: A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients with Advanced Solid Tumors. Dana-Farber - Harvard Cancer Center LAO; Do, Khanh Tu. (617) 632-6992

9930: A Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL). University Health Network Princess Margaret Cancer Center LAO; Chavez, Julio C. (813) 745-1867

Phase II

9875: Phase 2 Study of AT13387 (onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL. Dana-Farber - Harvard Cancer Center LAO; Jacobson, Caron Alyce. (617) 582-7591

9881: A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors. Yale University Cancer Center LAO; Kim, Joseph Woong. (203) 737-1600

Phase III

EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers. ECOG-ACRIN Cancer Research Group; Chaft, Jamie Erin. (646) 888-4543

Other Phases

10018: Randomized Trial of Financial Incentives for Research Participation. University of Pennsylvania/Abramson Cancer Center; Halpern, Scott David. (215) 898-1462

ACNS14B2-Q: Examination of Molecular Alterations of Potential Diagnostic, Prognostic and Therapeutic Utility Among Pediatric Low-Grade Gliomas (PLGGs) Treated on the Children’s Oncology Group Clinical Trial, A9952. Children’s Oncology Group; Eberhart, Charles G. (410) 502-5185

AOST15B2-Q: Validation of a Plasma MicroRNA Panel as a Biomarker for Osteosarcoma. Children’s Oncology Group; Allen-Rhoades, Wendy (832) 824-4207

ARST16B1-Q: Utilizing the Collaborative PedsTCC Infrastructure Towards Molecular Discovery of Novel Translocations and the Exomic Mutational Landscape in Embryonal Sarcoma. Children’s Oncology Group; Setty, Bhuvana Anantha. (614) 722-3550

ARST16B2-Q: Investigating the Role of the Transcriptional Co-Activator TAZ (Transcriptional Co-Activator with PDZ-Binding Motif) in Alveolar Rhabdomyosarcoma. Children’s Oncology Group; Linardic, Corinne Mary. (919) 684-3401

EAQ152: COMET - Communication and Education in Tumor Profiling: A Randomized Study of Pre-Disclosure Genetic Education v. Usual Care in Tumor Profiling for Advanced Cancer and a Pilot Study of Remote Genetic Counseling for Participants with Potential Germline Mutations Identified on Tumor Profiling. ECOG-ACRIN Cancer Research Group; Bradbury, Angela R. (215) 615-3341